MedTrace Logo

Imaging Biomarkers in Spastic Paraplegia Type 5

NCT05174403 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2023-08-22

No results posted yet for this study

Summary

This is a research study aiming to identify imaging biomarkers in patients diagnosed with spastic paraplegia type 5 (SPG5)

Conditions

  • Spastic Paraplegia Type 5A, Recessive

Interventions

OTHER

Cerebral and spinal cord magnetic resonance imaging

Cerebral and spinal cord magnetic resonance imaging (without injection of contrast medium). Patient's data will be compared to calibrated data from the commercially available medical software Brain Quant (licence BT-BQ-001-START, market CAIH, CE12331).

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Fanny MOCHEL, MD, PhD · Sorbonne Universités - Université Pierre et Marie Curie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-28
Primary Completion
2023-07-25
Completion
2023-07-25

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05174403 on ClinicalTrials.gov